• Profile
Close

Comparative effectiveness of β-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients

Circulation: Cardiovascular Quality and Outcomes Jul 17, 2019

Shavadia JS, et al. - In order to clearly determine the advantage of β-blocker use beyond 3 years following a myocardial infarction (MI), researchers analyzed patients ≥65 years of age with MI, discharged on β-blocker therapy and alive 3 years later without a recurrent MI in this observational analysis. They linked data from the CRUSADE Registry (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) to Medicare claims, to assess β-blocker use and dose (none, <50%, and ≥50% of the recommended target) at 3 years. Findings revealed no link between β-blocker use beyond 3 years after MI and improved outcomes, this was noted irrespective of the dose achieved. There is a need for further exploration of the role of prolonged β-blocker use, especially in older adults.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay